Congress trades
Sarepta Therapeutics, Inc. (SRPT)
Free on iOS and Android.
About Sarepta Therapeutics, Inc.
from the company's filings and listing, as of Oct 21, 2026- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Chief executive
- Michael E. Severino
- Employees
- 835
- Listed since
- Jun 4, 1997
- Market value
- $2.0B
- Price to earnings (12 mo)
- -
- Net income per share, as reported (12 mo)
- -$1.30
- Dividend yield
- -
Earnings
6 reported quarters · next on Nov 4, 2026| Quarter | EPS | EPS expected | Revenue | Revenue expected | Result |
|---|---|---|---|---|---|
| Q2 FY2026reported Aug 5, 2026 | -$0.05 | $0.22 | $401.3M | $366.4M | EPS miss, GAAPRevenue beat |
| Q1 FY2026reported May 6, 2026 | $3.16 | $0.98 | $730.8M | $474.2M | EPS beatRevenue beat |
| Q4 FY2025reported Feb 25, 2026 | -$3.58 | -$1.03 | $442.9M | $369.6M | EPS missRevenue beat |
| Q3 FY2025reported Nov 3, 2025 | -$1.80 | -$0.73 | $399.4M | $335.8M | EPS miss, GAAPRevenue beat |
| Q2 FY2025reported Aug 6, 2025 | $2.02 | $0.83 | $611.1M | $530.7M | EPS beatRevenue beat |
| Q1 FY2025reported May 6, 2025 | -$4.60 | -$0.87 | $744.9M | $687.5M | EPS miss, GAAPRevenue beat |
Actual against the consensus estimate at the time. A flag marks a beat or a miss of more than 1.5% either way; inside that band the quarter is in line. A flag marked GAAP compares a GAAP figure the company reported with an adjusted consensus, two different measures, so a one-time gain or charge can move it either way. A flag reads n/a only when a number is missing. Quarterly EPS is the figure set against the consensus, usually adjusted, so the quarters need not add up to the 12-month net income per share above. An estimate is a forecast made by analysts, not a company target.
Executive pay
as filed for fiscal 2025 · proxy filed Apr 24, 2026| Executive | Salary | Stock awards | Other | Total |
|---|---|---|---|---|
| Douglas S. IngramChief Executive Officer | $1.2M | $6.0M | $669K | $7.8M |
| Louise Rodino-Klapac, Ph.D.President, Research and Development and Technical Operations | $753K | $2.6M | $1.1M | $4.5M |
| Ian M. EstepanPresident, Chief Operating Officer | $741K | $2.6M | $1.1M | $4.4M |
| Ryan H. WongExecutive Vice President, Chief Financial Officer | $480K | $2.2M | $553K | $3.2M |
The summary compensation table from the proxy statement for fiscal 2025, with titles as filed then. 2 executives who have since left the company are named in that filing and not shown here. Read the filing
Institutional holders
13F positions as of Jun 30, 2026| Holder | Value | Shares | Shares vs prior qtr | % of shares out |
|---|---|---|---|---|
| BlackRock, Inc. | $341.3M | 18,994,958 | +28.7% | 18.02% |
| State Street Corp | $160.2M | 8,916,090 | +34.8% | 8.49% |
| Vanguard Portfolio Management LLC | $150.5M | 8,377,470 | +26.2% | 7.95% |
| Two Sigma Investments, LP | $82.6M | 4,598,735 | +0.1% | 4.36% |
| Vanguard Capital Management LLC | $82.5M | 4,591,755 | +0.3% | 4.36% |
| First Trust Advisors LP | $78.5M | 4,365,951 | +5.6% | 4.14% |
| AQR Capital Management LLCCliff Asness | $76.9M | 4,325,689 | -32.8% | 4.10% |
| Geode Capital Management, LLC | $49.8M | 2,771,758 | +39.4% | 2.63% |
| Erste Asset Management GmbH | $45.5M | 2,568,945 | -13.5% | 2.44% |
| Marshall Wace, LLP | $39.6M | 2,206,022 | +204.3% | 2.09% |
| Morgan Stanley | $39.6M | 2,202,641 | -15.2% | 2.09% |
| Aberdeen Group PLC | $39.4M | 2,194,948 | -5.3% | 2.08% |
A 13F reports long US equity positions and is filed within 45 days of the quarter end, so these are positions as they stood on Jun 30, 2026. For a manager's whole book see the fund directory. What a 13F covers and leaves out is explained in our guide to Form 13F.
GetSignal watches Form 4 and STOCK Act filings and pushes each one to your phone as it is published, with the history behind it. Free on iOS and Android.
Congress trades in SRPT
17 disclosures of 17 on record · median 35d of the 45 allowedSince the trade: the stock's move from its estimated entry price (a purchase) or estimated exit price (a sale) to its current price, the latest close we hold. Not the member's result.
| Member | Type | Action | Amount disclosed | Since the trade | Trade date | Disclosed | Delay |
|---|---|---|---|---|---|---|---|
| Gilbert Ray Cisneros, Jr. | Stock | Sale | $1,001 - $15,000 | -67.5% since the saleEstimated exit price $54.63, close on Mon Apr 14, 2025Current price $17.73, close on Fri Oct 23 | Apr 14, 2025 | May 6, 2025 | 22d |
| Josh GottheimerJoint | Stock | Purchase | $1,001 - $15,000 | n/a | Jul 14, 2023 | Aug 21, 2023 | 38d |
| Josh GottheimerJoint | Stock | Sale | $1,001 - $15,000 | n/a | Jun 13, 2023 | Jul 11, 2023 | 28d |
| Daniel S. Goldman | Stock | Sale | $15,001 - $50,000 | n/a | Apr 10, 2023 | May 19, 2023 | 39d |
| Josh GottheimerJoint | Stock | Purchase | $1,001 - $15,000 | n/a | Mar 6, 2023 | Apr 20, 2023 | 45d |
| Daniel S. Goldman | Stock | Purchase | $15,001 - $50,000 | n/a | Mar 6, 2023 | Apr 17, 2023 | 42d |
| Daniel S. Goldman | Stock | Sale | $1,001 - $15,000 | n/a | Jan 31, 2023 | Feb 24, 2023 | 24d |
| Josh GottheimerJoint | Stock | Sale | $1,001 - $15,000 | n/a | Nov 6, 2020 | Dec 9, 2020 | 33d |
| Gilbert Ray Cisneros, Jr. | Stock | Purchase | $1,001 - $15,000 | n/a | Sep 14, 2020 | Oct 14, 2020 | 30d |
| Gilbert Ray Cisneros, Jr. | Stock | Sale | $1,001 - $15,000 | n/a | Jun 10, 2020 | Jul 17, 2020 | 37d |
| Josh GottheimerJoint | Stock | Purchase | $1,001 - $15,000 | n/a | Dec 13, 2019 | Jan 6, 2020 | 24d |
| Gilbert Ray Cisneros, Jr. | Stock | Purchase | $1,001 - $15,000 | n/a | Oct 10, 2019 | Nov 15, 2019 | 36d |
| Gilbert Ray Cisneros, Jr. | Stock | Purchase | $1,001 - $15,000 | n/a | Oct 11, 2019 | Nov 15, 2019 | 35d |
| Gilbert Ray Cisneros, Jr. | Stock | Purchase | $1,001 - $15,000 | n/a | Apr 9, 2019 | May 14, 2019 | 35d |
| Gilbert Ray Cisneros, Jr. | Stock | Purchase | $1,001 - $15,000 | n/a | Mar 11, 2019 | Apr 16, 2019 | 36d |
| Gilbert Ray Cisneros, Jr. | Stock | Purchase | $1,001 - $15,000 | n/a | Feb 26, 2019 | Mar 8, 2019 | 10d |
| Gilbert Ray Cisneros, Jr. | Stock | Purchase | $1,001 - $15,000 | n/a | Feb 27, 2019 | Mar 8, 2019 | 9d |
Estimated prices are the stock's closing price on the trade date. A disclosure gives a value band, not the price paid. Not investment advice. After a sale a positive figure means the stock kept rising after it. On an option line the prices are the stock's, never the option's: the premium is never disclosed.
A delay above 45 days is the gap between the dates on the report; we mark a filing late only after checking it.
"Not captured" means the band or the transaction type on the original report is missing from our data.
"Dates conflict" marks a row whose disclosure is dated before its trade on the record we hold. Both dates are printed as filed, and no prices or move are shown for that row.
Every Congress trade in SRPT, filterable by party, chamber, type and account.
Questions
Which members of Congress have traded SRPT?
Gilbert Ray Cisneros, Jr., Josh Gottheimer and Daniel S. Goldman disclosed SRPT transactions in the filings shown here.
How quickly are SRPT trades disclosed?
Congressional disclosures took a median of 35 days, against the 45 the STOCK Act allows.
How to read a STOCK Act filing
WHAT THE FILING ACTUALLY SAYS
Congress rows disclose a value range rather than an exact amount, and the STOCK Act allows up to 45 days to report. Full sourcing and the limits of this data are on the methodology page. A filing is a record of a transaction, not a signal, and nothing here is investment advice.
Data as of Oct 27, 2026.